Opioid addiction is a chronic relapsing disease affecting at least 2 million Americans with an associated annual mortality approaching 50,000 deaths. Currently available interventions have proven ineffective in addressing this public health crisis. Over the past several decades, significant progress has been made in identifying the neural mechanisms of opioids. Like other drugs of abuse, opioids activate the mesolimbic dopamine pathway, increasing the excitability of dopaminergic neurons in the ventral tegmental area (VTA) and enhancing dopamine neuromodulation via projections to a variety of targets. The effects of mesolimbic dopamine activation in mice are well studied and include heightened locomotor activity. One VTA target, the nucleus accumbens (NAc), is thought to act as a ?rheostat? of reward, and fluctuations in dopamine release in this region appear to control whether stimuli are perceived as rewarding or aversive. Beyond acute effects, repeated administration of opioids demonstrates that these drugs are capable not only of modifying dopamine release but also of inducing plasticity in the dopamine response. For example, in a phenomenon known as psychomotor sensitization, repeated exposure to a fixed dose of opioid produces a progressive increase in locomotion. As a neural correlate of sensitization, opioids are known to induce alterations in the density of synaptic contacts onto the dominant neuronal population in the NAc, medium spiny projection neurons (MSNs). These changes likely modify the internal circuit dynamics of the NAc to accentuate drug reward and reinforcement, contributing to the development addiction and relapse. However, a dearth of knowledge concerning opioid-induced changes to the microcircuitry of key neural reward substrates presents a significant barrier to the rational design of therapies aimed at preventing opioid-induced synaptic rewiring. MSNs are heterogenous, consisting of at least two subpopulations, distinguishable by their expression of the D1-dopamine receptor or the D2-dopamine receptor. D1-MSNs appear to promote addictive behaviors while D2-MSNs may oppose these behaviors. Despite the functional significance of these differences, the cell-type specificity of opioid-induced morphologic changes has not been investigated. The proposed experiments will examine subtype-specific structural plasticity of excitatory and inhibitory synapses onto MSNs in the NAc in response to repeated morphine exposure. We will then evaluate the same parameters in a mutant known to exhibit attenuated psychomotor sensitization to determine whether subtype- specific spine changes by this mutation.
The current proposal aims to address significant gaps in our understanding of opioid induced structural plasticity in the nucleus accumbens. Elucidating specific mechanisms of durable, maladaptive neuroplasticity induced by repeated exposure to opioids will contribute to the development of novel therapeutics that prevent or reverse these adaptations, potentially reducing the risk of dependence that accompanies exposure to opioid drugs. The long-term goal of this proposal is to support the development of effective treatments for opioid addiction, a major public health concern.
